Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Open Label Study in Previously Studied, SBC-103 Treatment Naive MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously

Next Previous
Trial Profile

A Phase I/II Open Label Study in Previously Studied, SBC-103 Treatment Naive MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lesinidase alfa (Primary)
  • Indications Mucopolysaccharidosis III
  • Focus Adverse reactions
  • Acronyms CL01-T
  • Sponsors Alexion AstraZeneca Rare Disease; Synageva BioPharma

Most Recent Events

  • 19 Apr 2018 Status changed from active, no longer recruiting to discontinued.
  • 03 Feb 2016 According to an Alexion Pharmaceuticals media release, Six-month data will be presented as a late-breaker abstract at the WORLDSymposium 2016 meeting.
  • 01 Dec 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top